<DOC>
	<DOCNO>NCT00271479</DOCNO>
	<brief_summary>Hypothesis : Lower dos A/C/Y/W135 component meningococcal polysaccharide vaccine could confer similar functional immunogenic response dose 50 μg currently use , subsequently equally protective . The purpose study evaluate use fractional dose tetravalent meningococcal polysaccharide vaccine control outbreak especially cause N. meningitidis serogroup W135 Primary Objectives : - To measure immunogenicity dose correspond one fifth amount license meningococcal A/C/Y/W135 polysaccharide vaccine , i.e . 10 μg component ; - To measure immunogenicity dose correspond one tenth license meningococcal A/C/Y/W135 polysaccharide vaccine , i.e . 5 μg component .</brief_summary>
	<brief_title>Fractional Dose Tetravalent A , C , Y , W135 Meningococcal Polysaccharide Vaccine</brief_title>
	<detailed_description>In 2002 , epidemic meningococcal disease start Burkina Faso Neisseria meningitidis serogroup W135 identify causative organism . This event follow outbreak 2000 2001 Mecca , Saudi Arabia , first large epidemic cause serogroup W135 . Mass vaccination population vaccine protect W135 , i.e . tetravalent A/C/Y/W135 polysaccharide vaccine ( TPSV ) , possible global shortage supply , addition cost . In 2003 , GlaxoSmithKline ( GSK ) produce trivalent polysaccharide vaccine A/C/W135 US $ 1.5 . This vaccine use Burkina Faso new epidemic face country 2003 . However , availability affordability tetravalent A/C/Y/W135 polysaccharide vaccine trivalent A/C/W135 polysaccharide vaccine still discussion WHO producer . The risk epidemic due W135 strain African country high concern scientific community . The current dose license tetravalent A/C/Y/W135 polysaccharide vaccine contain 50 μg polysaccharide component . During 1980 ’ , researcher Walter Reed Army Institute Research ( WRAIR ) extensive work immunogenicity meningococcal polysaccharide vaccine adult . A first study perform Griffiss et al . demonstrate dose 5 μg group Y group W135 polysaccharides effective dos 50 μg induce production bactericidal antibody amount correlate functional immunity ( Griffiss et al . Mil Med 1985 ; 150 : 529-33 ) . A second study conclude dos 7.5 μg ( Y W ) 15 μg ( A C ) sufficient induce equivalent bind bactericidal antibody responses 50 μg ( Griffiss et al . Infect Immun 1982 ; 37 : 205-8 ) . In recent study Granoff et al. , 1/50 ( 1 mcg ) ordinary dose tetravalent A/C/Y/W135 vaccine give ( Granoff et al . J Infect Dis 1998 ; 178 : 870-4 ) . The antibody responses A C measure , low dose sufficient mount C response subject , dose less effective elicit response A . The antibody responses W135 Y report . Hypothesis : Lower dos A/C/Y/W135 component meningococcal polysaccharide vaccine could confer similar functional immunogenic response dose 50 μg currently use , subsequently equally protective . It would potentially bring two major benefit . Firstly , would increase number tetravalent vaccine dose available market . Secondly , would decrease cost individual vaccine dose . As result , people could vaccinate , thereby protected disease , low price . Results obtain study tetravalent A/C/Y/W135 polysaccharide vaccine would valid trivalent A/C/W135 polysaccharide vaccine .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Volunteers suffer severe chronic disease know congenital acquire immunodeficiency . A medical exam perform medical doctor inclusion . Volunteers must live Mbarara district within 15 km site immunization . Volunteers resident choose site express plan move area study period . Volunteers must available followup duration study ( minimum 24 month ) . Volunteers severe chronic disease general condition require hospital admission . Volunteers know congenital acquire immunodeficiency ( e.g . HIV ) . Diagnosis presumptive base medical background clinical examination . No serological HIV testing perform . Evidence concomitant infection time presentation ( include rash scabies ; ear , nose throat infection ; abnormal respiratory system examination ) . The patient underlie disease compromise diagnosis evaluation response study medication . History serious adverse reaction vaccine anaphylaxis relate symptom hive , respiratory difficulty , angioedema abdominal pain . Malnutrition : The nutritional assessment child age 24–59 month , weightforheight ( W/H ) index , calculate . This index express standard deviation normalise distribution reference population 38 ( National Centre Health Statistics , USA ) . Children 5 year old Zscore inferior 2 exclude . For child 5 adult , clinical examination consider . Pregnant woman lactate woman eligible trial . All woman childbearing age must provide urine sample pregnancy test inclusion , subgroup “ b ” , second vaccine injection .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Dose-Response Relationship , Immunologic</keyword>
	<keyword>Neisseria meningitidis</keyword>
	<keyword>Outbreaks</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Africa</keyword>
	<keyword>Uganda</keyword>
	<keyword>Prevention Neisseria meningitidis infection</keyword>
	<keyword>In outbreak contexts develop country</keyword>
</DOC>